{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-23-000038","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.876366+00:00","generated_at":"2026-06-15T19:47:53.425743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"BD Q2 fiscal 2023 revenue $4.82B, adjusted EPS $2.86; raises guidance","bullets":["Revenue $4.821B, up 1.5% reported (+4.1% currency-neutral); base revenue (ex-COVID) up 6.0% reported (+8.7% currency-neutral).","GAAP diluted EPS $1.53; adjusted diluted EPS $2.86, up 2.9% reported (+11.2% currency-neutral).","Company raises full-year base revenue and adjusted EPS guidance midpoints, enabling additional growth investments.","FDA approval for BD Onclarity HPV assay with SurePath and ThinPrep; BD Vaginal Panel cleared for BD COR system; BD Prevue II system launched."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-23-000038","json":"https://secwatch.observer/filing/0000010795-23-000038.json","markdown":"https://secwatch.observer/filing/0000010795-23-000038.md","text":"https://secwatch.observer/filing/0000010795-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/0000010795-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/bdx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:47:53.425743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1142dbc853d77c0ecc0cf29b2542f09f261ea17a","claim":"BECTON DICKINSON & CO reported second quarter of fiscal 2023 results: revenue $4.8 billion, EPS $1.53. Guidance raised.","evidence_excerpt":"BD Reports Second Quarter Fiscal 2023 Financial Results BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges • Revenue of $4.8 billion increased 1.5% as reported and 4.1% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.0% as reported, 8.7% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.53 and $2.86, respectively • Company raises full-year base revenue guidance, enabling additional investments in growth and innovation while absorbing lower COVID-only diagnostic testing revenue and incremental FX impacts","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10795/000001079523000038/0000010795-23-000038-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2023"},{"label":"Revenue","value":"$4.8 billion"},{"label":"EPS","value":"$1.53"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}